Effect of Drug Clinical Trial
Official title:
The Effect of Oxycodone Hydrochloride on Catheter-related Bladder Discomfort After TURBT Under General Anesthesia
The purpose of this study is to investigate the effect of Oxycodone Hydrochloride on catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor after general anesthesia.
Catheter-related bladder discomfort(CRBD) is a frequent complication after indwelling catheter under general anesthesia. The incidence of CRBD in patients undergoing Transurethral resection is as high as 66.7-91.2%.CRBD may lead some poor prognosis including postoperative restlessness, bleeding, and circulatory instability.therefore，how to reduce the incidence of CRBD is one of the urgent problems to be solved in clinic. Oxycodone Hydrochloride is a strong opioid receptor agonist used in clinic at present. It has certain advantages in the regulation of visceral pain and can produce analgesic effect without causing restlessness, gastrointestinal motility inhibition and respiratory inhibition through stimulating the μ and κ opioid receptor simultaneously. However, the effect of Oxycodone Hydrochloride on catheter-related bladder discomfort in patients undergoing transurethral resection of bladder tumor after general anesthesia is still unknown. The purpose of this study is to explore whether Oxycodone Hydrochloride via intravenous injection could reduce the incidence of CRBD in patients undergoing transurethral resection of bladder tumor after general anesthesia and could not increase other complications during the recovery period of general anesthesiathe. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04549012 -
Determination of Blood Loss After CS
|
Early Phase 1 | |
| Active, not recruiting |
NCT06114758 -
Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
|
||
| Completed |
NCT05076253 -
Efficacy of Ivermectin in COVID-19
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04573049 -
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
|
Phase 4 | |
| Not yet recruiting |
NCT04562493 -
Comparative Effect of Transforaminal Injection of Magnesium Sulphate Versus Ozone Therapy on Oxidative Stress Biomarkers in Lumbar Disc Related Radicular Pain
|
N/A | |
| Completed |
NCT04762147 -
Comparison of Perioperative Analgesia Between Intravenous Paracetamol and Fentanyl for Rigid Hysteroscopy
|
Phase 3 | |
| Completed |
NCT06432309 -
Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease
|
N/A | |
| Recruiting |
NCT05092074 -
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
|
||
| Recruiting |
NCT05968885 -
Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity
|
Phase 4 | |
| Recruiting |
NCT05595044 -
Effect of Vitamin D Therapy in Autism Spectrum Disorder
|
Phase 1 | |
| Not yet recruiting |
NCT06100510 -
PFA 100 Evaluation and Reference Interval HOACNY
|
Phase 4 | |
| Completed |
NCT05060913 -
Emla Cream Versus Benzocaine on Analgesia
|
Early Phase 1 | |
| Not yet recruiting |
NCT05293119 -
Role of Tofacitinib in Vitiligo Patients
|
Early Phase 1 | |
| Not yet recruiting |
NCT06414018 -
Effect of Equivalent Dose Sufentanil and Afentanil in Bronchoscopic Treatment
|
N/A | |
| Recruiting |
NCT05786859 -
The Efficacy and Safety of Rifaximin Treatment
|
Early Phase 1 | |
| Not yet recruiting |
NCT06290219 -
The Effect of Platelet-rich Plasma Nasal Injection in the Treatment of Traumatic Olfactory Dysfunction
|
Phase 3 | |
| Completed |
NCT05277480 -
Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)
|
Phase 2 | |
| Recruiting |
NCT05482451 -
Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer
|
Early Phase 1 | |
| Not yet recruiting |
NCT04892212 -
Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05918146 -
Dextrose Therapy on Physical Therapy in Subdeltoid Bursitis
|
Phase 4 |